U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07115927) titled 'pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer' on Aug. 04.
Brief Summary: RODEO is a window of opportunity trial using dostarlimab in patients with newly diagnosed high-risk (stage 2-4) endometrial cancer who are suitable for primary surgery. Patients will receive 2 doses of dostarlimab (500mg IV day 1 and day 22) prior to surgery. The primary objective is to assess the pathological response rate to pre-operative dostarlimab and the secondary objectives are to assess the feasibility, toxicity, safety and efficacy of pre-operative dostarlimab.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
E...